UK markets open in 4 hours 1 minute

Bayer Aktiengesellschaft (0P6S.IL)

IOB - IOB Delayed price. Currency in EUR
Add to watchlist
51.91-0.17 (-0.33%)
At close: 06:14PM BST
Full screen
Previous close52.08
Open52.28
Bid51.38 x 0
Ask52.44 x 0
Day's range51.77 - 52.69
52-week range6.00 - 67.99
Volume2,614,769
Avg. volume2,630,147
Market cap51.248B
Beta (5Y monthly)1.15
PE ratio (TTM)23.17
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield2.00 (3.74%)
Ex-dividend date03 May 2022
1y target estN/A
  • Zacks

    Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q2

    Bayer (BAYRY) beats estimates for both earnings and revenues in the second quarter of 2022.

  • Reuters

    Bayer says arbitration ruling over BASF claims is imminent

    Bayer's chief executive said an arbitration court would soon decide on claims brought by rival BASF, saying it overpaid for assets that Bayer sold to secure antitrust clearance for the takeover of Monsanto. Bayer CEO Werner Baumann told analysts in a call on Thursday that the ruling was expected "shortly" and that there was hardly any potential to seek recourse should Bayer disagree with the verdict. BASF in 2019 took Bayer to a previously agreed arbitration court, claiming that Bayer had not fully disclosed personnel costs when it negotiated the sale of two assets bundles.

  • Reuters

    Bayer's agriculture unit, consumer health drive outlook hike

    FRANKFURT (Reuters) -Agriculture and pharmaceuticals company Bayer on Thursday lifted its 2022 earnings guidance on strong demand from farmers for its seeds and crop chemicals and higher sales of consumer health products. Bayer is now targeting earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for special items, of about 13 billion euros ($13.21 billion), based on June 30 foreign exchange rates, where it had previously predicted about 12 billion euros, it said in a statement. Bayer, which has been hit by litigation costs over claims that a weedkiller it acquired under its Monsanto takeover causes cancer, said that second-quarter adjusted EBITDA jumped 30% to 3.35 billion euros, above an average analyst estimate of 3.28 billion euros posted on the company's website.